Widening for clopidogrel BE study [Outliers]

posted by Loky do – Egypt, 2021-06-16 17:08 (43 d 11:00 ago) – Posting: # 22420
Views: 660

» You linked the EMA Q&A where it is stated unequivocally:
» Under these circumstances, the widening of 90% confidence intervals for Cmax is not recommended.

Ok, in my case, the study fails as per EMA guidance, but if we used the FDA method for calculations it passes, regarding a drug as clopidogrel with many therapeutic issues, could it be accepted by different authorities, considering FDA guidelines (sponsor requests to submit an appeal to authorities to use calculations as per FDA guidelines as the protocol uses EMA guidance for statistical calculations)?
thanks

Complete thread:

Activity
 Admin contact
21,592 posts in 4,514 threads, 1,532 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time: Friday 04:08 CEST (Europe/Vienna)

It is a capital mistake to theorise before one has data.    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5